The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
These are truly transformative times in the field of hematologic malignancies. Diseases that were once considered untreatable are now being managed—and in some cases cured—thanks to cutting-edge therapies. Just a few years ago, such outcomes would have seemed unimaginable. However, as we travel the world, we are constantly reminded of the urgent need to make these advancements accessible on a global scale.
Andrew Wei, MBBS, PhD, previews this year’s AML session starting at 3:51 pm today, September 3
Artificial intelligence (AI) has seen a staggering influx of investment across nearly every sector, and hematologic oncology is no exception. While some may think AI is overhyped, others believe it is poised to revolutionize the way hematologic oncologists approach the diagnosis, treatment, and understanding of blood cancers.
The Society of Hematologic Oncology has released the SOHO 2025 program book, detailing the Thirteenth Annual Meeting, set for September 3–6, 2025, at the George R. Brown Convention Center in Houston.
In September 2012, the Society of Hematologic Oncology (SOHO) began with just 400 members and a vision to bring the knowledge of the leading minds from the University of Texas MD Anderson to unite the global blood cancer community.
Register today at soho.click/2025. Become a member at soho.click/join.
Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Phillip Scheinberg, MD, president of the Society of Hematologic Oncology (SOHO), chat about SOHO’s vision, […]
